New study to tackle HIV multi-drug resistance launches
In London and Edinburgh, researchers have begun recruiting participants for a new study aimed at better understanding and overcoming HIV multi-drug resistance.
On week one participants will be randomised to one of four blinded arms. Alongside their current, failing, combinations they will receive islatravir, doravirine, both drugs or a placebo.
From week two all participants will receive open-label islatravir and doravirine to an optimised background ART for the next 48 weeks.